BioNTech’s Marburg facility gets EMA approval, boosting COVID-19 vaccine production capacity by a billion doses a year


BioNTech SE
said Friday that the European Medicines Agency (EMA) has approved its Marburg facility in Germany for the manufacture of the COVID-19 vaccine drug substance, which would boost annual vaccine production capacity by one billion does a year when full operational. BioNTech, which along with U.S.-based partner Pfizer Inc.
makes the COVID-19 vaccine, said it can now deliver the drug product batches of the vaccine to partner sites, for sterile fill and finish, and expects the first batches of the vaccines made at the Marburg site to be delivered in the second half of April. The company said there are 50,000 steps required from manufacturing the drug substance, mRNA, to the bulk drug substance which then can be filled and finished. BioNTech’s stock rose 1.6% in morning trading, while Pfizer shares gained 0.3% and the S&P 500
tacked on 0.5%.


Leave A Reply

Your email address will not be published.